Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease

Nephro-urology Monthly
Omid SedighiBatoul Omranifar

Abstract

Beta-2 microglobulin (B2M) is considered as a surrogate marker for middle molecule uremic toxins and a key component in dialysis-related amyloidosis. However, few studies have evaluated role of B2M in patients with chronic kidney disease (CKD). The purpose of this study was to evaluate the association of plasma B2M level with some metabolic and cardiac performance factors in patients with CKD. In this case-control study, we measured plasma B2M level in 86 patients with different stages of CKD and 78 age- and sex-matched individuals, as healthy control group. Then we investigated the association between plasma B2M level and left ventricular hypertrophy, ejection fraction (EF), and left ventricular end-diastolic diameter (LVEDD) in echocardiography and some inflammatory and metabolic factors in patients with CKD. Mean plasma B2M level was significantly higher in patients with CKD than in control group (P < 0.001). It was directly correlated with serum C-reactive protein (r = 0.167, P < 0.001), phosphate (r = 0.112, P < 0.001) levels, and left ventricular mass index (r = 0.438, P < 0.001) and LVEDD (r = 0.275, P < 0.001) in echocardiography. It was also inversely correlated with glomerular filtration rate (r = -0.033, P < 0.001), ...Continue Reading

References

Jun 13, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J J KazamaF Gejyo
Dec 19, 2003·Advances in Renal Replacement Therapy·James F WinchesterNathan W Levin
Apr 9, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R VanholderUNKNOWN European Uremic Toxin Work Group
Oct 20, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuaki SaijoReiko Kishi
Dec 31, 2005·Journal of the American Society of Nephrology : JASN·Alfred K CheungGarabed Eknoyan
Jan 10, 2008·Blood Purification·Francesco LocatelliUNKNOWN Membrane Permeability Outcome (MPO) Study Group
Mar 28, 2008·Kidney International·C MenaaS M Sprague
Sep 19, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Senji OkunoYoshiki Nishizawa
Jul 21, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Björn K I MeijersPieter Evenepoel
Aug 28, 2009·Seminars in Dialysis·Tilman B Drüeke, Ziad A Massy
Nov 17, 2010·Blood Purification·Eva SchepersUNKNOWN European Uremic Toxin Work Group (EUTox)
Feb 9, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Pachiappan ChitraThayumanavan Palvannan
Feb 15, 2011·Scandinavian Journal of Clinical and Laboratory Investigation·Jaak KalsMihkel Zilmer
May 7, 2011·Stroke; a Journal of Cerebral Circulation·Jasmin AmighiOswald Wagner
Aug 17, 2012·Kidney International·Sophie LiabeufUNKNOWN European Uremic Toxin Work Group (EUTox)
Apr 11, 2013·European Journal of Endocrinology·Ching-Lung CheungBernard M Y Cheung

❮ Previous
Next ❯

Citations

May 16, 2020·International Journal of Nephrology·Justor BandaSaraladevi Naicker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.